REVLASIA – US Trademark 88175225 of Revance Therapeutics, Inc

Trademark image

REVLASIA (U.S. Trademark Serial Number 88175225) is a United States trademark of Revance Therapeutics, Inc. The goods and services include: Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, wrinkles, hyperhydrosis, sports injuries, namely, injured or torn skin, muscle, ligaments, or bone, cerebral palsy, muscle spasms, muscle tremors and pain; pharmaceutical preparations, namely, peptide substrates for use in the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, sports injuries, namely, injured or torn skin, muscle, ligaments, or bone, cerebral palsy, muscle spasms, muscle tremors and pain; body creams, lotions and gels for medical purposes; eye creams, lotions and gels for medical purposes . The correspondent is Maren C. Perry of KING & SPALDING LLP.

This trademark was filed on October 30, 2018 as United States Trademark Application Serial Number 88175225. This trademark application is still pending and does not yet have a registration number.

Trademark PTO Status History

July 04, 2022 – ABANDONMENT – NO USE STATEMENT FILED

October 26, 2021 – NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

October 25, 2021 – SOU EXTENSION 5 GRANTED

October 21, 2021 – SOU EXTENSION 5 FILED

October 21, 2021 – TEAS EXTENSION RECEIVED

May 13, 2021 – NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

May 12, 2021 – SOU EXTENSION 4 GRANTED

May 07, 2021 – SOU EXTENSION 4 FILED

View full trademark status information at USPTO

Ownership History

Revance Therapeutics, Inc

Revance Therapeutics, Inc

View documents on file at USPTO

File a Trademark or Get Help With Trademark Law

Select IP monitors top trademarks which have been allowed and granted worldwide. We are experts in trademark law. If you are interested in connecting with an IP law attorney or patent law attorney, please contact us via the contact form.